A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5

[1]  Thomas Yu,et al.  Abstract 4725: Multiple Myeloma DREAM Challenge: A crowd-sourced challenge to improve identification of high-risk patients , 2017 .

[2]  D. Landau,et al.  Genomic complexity of multiple myeloma and its clinical implications , 2017, Nature Reviews Clinical Oncology.

[3]  P. Campbell,et al.  A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma , 2016, Blood Cancer Journal.

[4]  Nikhil Wagle,et al.  The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine , 2016, Genome Medicine.

[5]  D. Hose,et al.  Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma , 2016, Haematologica.

[6]  G. Ahmann,et al.  Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients , 2016, Blood Cancer Journal.

[7]  M. Mohty,et al.  Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? , 2015, Blood.

[8]  S. Gabriel,et al.  Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution , 2015, Nature Communications.

[9]  G. Mulligan,et al.  Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. , 2015, Blood.

[10]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Obi L. Griffith,et al.  Genome Modeling System: A Knowledge Management Platform for Genomics , 2015, PLoS Comput. Biol..

[12]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[13]  L. Bullinger,et al.  Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P) , 2015, Annals of Hematology.

[14]  S. Mathew,et al.  A translocation t(2;14)(p11.2;q32) involving rearrangements of immunoglobulin heavy chain and kappa light chain genes in B-cell lymphoma , 2015, Leukemia & lymphoma.

[15]  L. Bullinger,et al.  Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease , 2015, British journal of haematology.

[16]  Ryan M. Layer,et al.  SpeedSeq: Ultra-fast personal genome analysis and interpretation , 2014, Nature Methods.

[17]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[18]  Eric J Duncavage,et al.  Copy number variants in clinical next-generation sequencing data can define the relationship between simultaneous tumors in an individual patient. , 2014, Experimental and molecular pathology.

[19]  Obi L. Griffith,et al.  SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution , 2014, PLoS Comput. Biol..

[20]  T. Cedena,et al.  Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. , 2014, Blood.

[21]  T. Chevassut,et al.  The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.

[22]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[23]  G. Morgan,et al.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.

[24]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[25]  Savita Shrivastava,et al.  Validation of a next-generation sequencing assay for clinical molecular oncology. , 2014, The Journal of molecular diagnostics : JMD.

[26]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[27]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[28]  G. Morgan,et al.  Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. , 2013, Blood.

[29]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[30]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[31]  Ryan M. Layer,et al.  LUMPY: a probabilistic framework for structural variant discovery , 2012, Genome Biology.

[32]  Matthew B. Callaway,et al.  MuSiC: Identifying mutational significance in cancer genomes , 2012, Genome research.

[33]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[34]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[35]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[36]  Ken Chen,et al.  SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..

[37]  D. Hose,et al.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. , 2012, Blood.

[38]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[39]  C. Perou,et al.  Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.

[40]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[41]  F. Alt,et al.  Mechanisms promoting translocations in editing and switching peripheral B cells , 2009, Nature.

[42]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[43]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[44]  R. Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[45]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[46]  R. Kaufman,et al.  Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation , 2006, The Journal of cell biology.

[47]  P. Loehrer,et al.  International Staging System for Multiple Myeloma , 2006 .

[48]  J. Delabie,et al.  t(14;22)(q32;q11) in non‐Hodgkin lymphoma and myeloid leukaemia: molecular cytogenetic investigations , 2005, British journal of haematology.

[49]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[50]  R. Bataille,et al.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. , 2001, Blood.

[51]  P. L. Bergsagel,et al.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  G. Ahmann,et al.  A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. , 1998, Cancer genetics and cytogenetics.

[53]  F. Mills,et al.  Enhancer Complexes Located Downstream of Both Human Immunoglobulin Cα Genes , 1997, The Journal of experimental medicine.

[54]  M. Kennedy.  Novel chromosome translocation caused by fusion of immunoglobulin heavy and light chain V genes in a human B lymphoblastoid cell line , 1991, The Journal of experimental medicine.

[55]  G. Kitchingman,et al.  Sequencing of selected regions of the human immunoglobulin heavy-chain gene locus that completes the sequence from JH through the delta constant region. , 1991, DNA sequence : the journal of DNA sequencing and mapping.

[56]  W. S. Hayward,et al.  Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus , 1984, Nature.